A study assessed the use of novel histone deacetylase inhibitor chidamide in patients with relapsed/refractory T-cell acute lymphocytic lymphoma/ and eukemia (T-LBL/ALL). The researchers concluded that chidamide combined with chemotherapy may be a beneficial treatment for patients with T-LBL/ALL.
A total of 17 patients received combination chidamide and chemotherapy salvage treatment, and a historical cohort of patients receiving chemotherapy alone was assessed.
After one course of treatment, the complete and overall response rates were higher in the chidamide plus chemotherapy group compared with the chemotherapy alone group. The chidamide plus chemotherapy group also had better progression-free survival. Overall survival did not differ between the groups. In the chidamide plus chemotherapy group, grade 3/4 non-hematologic adverse events (occurring in >10% of patients) included febrile neutropenia (64.7%), drug-induced liver failure (17.6%), decreased fibrinogen (11.8%), sepsis (11.8%), pneumonitis (11.8%), and oral mucositis (11.8%).
“This study demonstrates that a chidamide-included regimen may be a new treatment strategy with an acceptable safety profile for patients with relapsed/refractory T-LBL/ALL but requires further investigation,” the authors concluded.